CN112210571B - 表达iss基因的新城疫LaSota弱毒疫苗株反向遗传操作系统、其构建方法及应用 - Google Patents
表达iss基因的新城疫LaSota弱毒疫苗株反向遗传操作系统、其构建方法及应用 Download PDFInfo
- Publication number
- CN112210571B CN112210571B CN202010883843.6A CN202010883843A CN112210571B CN 112210571 B CN112210571 B CN 112210571B CN 202010883843 A CN202010883843 A CN 202010883843A CN 112210571 B CN112210571 B CN 112210571B
- Authority
- CN
- China
- Prior art keywords
- iss
- ndv
- newcastle disease
- plasmid
- pbr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000010359 Newcastle Disease Diseases 0.000 title claims abstract description 64
- 238000010276 construction Methods 0.000 title claims abstract description 55
- 229940031567 attenuated vaccine Drugs 0.000 title claims abstract description 48
- 230000002068 genetic effect Effects 0.000 title claims abstract description 35
- 230000002441 reversible effect Effects 0.000 title claims abstract description 33
- 101150029141 iss gene Proteins 0.000 title description 23
- 239000013612 plasmid Substances 0.000 claims abstract description 127
- 238000013518 transcription Methods 0.000 claims abstract description 49
- 230000035897 transcription Effects 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 38
- 230000008569 process Effects 0.000 claims abstract description 33
- 230000003321 amplification Effects 0.000 claims abstract description 32
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 32
- 239000002299 complementary DNA Substances 0.000 claims abstract description 30
- 238000001976 enzyme digestion Methods 0.000 claims abstract description 29
- 241000700605 Viruses Species 0.000 claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 27
- 229960005486 vaccine Drugs 0.000 claims abstract description 22
- 239000013598 vector Substances 0.000 claims description 26
- 241000271566 Aves Species 0.000 claims description 18
- 230000014509 gene expression Effects 0.000 claims description 17
- 230000001717 pathogenic effect Effects 0.000 claims description 16
- 239000000872 buffer Substances 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 238000011144 upstream manufacturing Methods 0.000 claims description 12
- 238000012408 PCR amplification Methods 0.000 claims description 11
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 9
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 238000003752 polymerase chain reaction Methods 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 6
- 102000053642 Catalytic RNA Human genes 0.000 claims description 5
- 108090000994 Catalytic RNA Proteins 0.000 claims description 5
- 108010061100 Nucleoproteins Proteins 0.000 claims description 5
- 102000011931 Nucleoproteins Human genes 0.000 claims description 5
- 102000007982 Phosphoproteins Human genes 0.000 claims description 5
- 108010089430 Phosphoproteins Proteins 0.000 claims description 5
- 108010026228 mRNA guanylyltransferase Proteins 0.000 claims description 5
- 238000010839 reverse transcription Methods 0.000 claims description 5
- 108091092562 ribozyme Proteins 0.000 claims description 5
- 244000144977 poultry Species 0.000 claims description 4
- 208000005331 Hepatitis D Diseases 0.000 claims description 3
- 208000037262 Hepatitis delta Diseases 0.000 claims description 3
- 208000029570 hepatitis D virus infection Diseases 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 101710163270 Nuclease Proteins 0.000 claims description 2
- 238000009395 breeding Methods 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 241000588722 Escherichia Species 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 abstract description 8
- UXUFTKZYJYGMGO-CMCWBKRRSA-N (2s,3s,4r,5r)-5-[6-amino-2-[2-[4-[3-(2-aminoethylamino)-3-oxopropyl]phenyl]ethylamino]purin-9-yl]-n-ethyl-3,4-dihydroxyoxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(=O)NCCN)=CC=3)=NC(N)=C2N=C1 UXUFTKZYJYGMGO-CMCWBKRRSA-N 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 42
- 241000711404 Avian avulavirus 1 Species 0.000 description 23
- 239000012634 fragment Substances 0.000 description 22
- 241000287828 Gallus gallus Species 0.000 description 21
- 239000000047 product Substances 0.000 description 17
- 235000013330 chicken meat Nutrition 0.000 description 15
- 210000003837 chick embryo Anatomy 0.000 description 12
- 238000012360 testing method Methods 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 238000012258 culturing Methods 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 238000000605 extraction Methods 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000007758 minimum essential medium Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 210000000078 claw Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 235000013594 poultry meat Nutrition 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108050009160 DNA polymerase 1 Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 206010061126 Escherichia infection Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 208000027954 Poultry disease Diseases 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003278 egg shell Anatomy 0.000 description 2
- 239000006153 eosin methylene blue Substances 0.000 description 2
- 208000020612 escherichia coli infection Diseases 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241001447918 Baoris Species 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 101150084044 P gene Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241001523486 Poncirus Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940012466 egg shell membrane Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18151—Methods of production or purification of viral material
- C12N2760/18152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18161—Methods of inactivation or attenuation
- C12N2760/18162—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
5×TransStart FastPfu Buffer | 5μL |
2.5mM dNTPs | 2μL |
模板 | 2μL |
F(上游引物) | 0.5μL |
R(下游引物) | 0.5μL |
TransStart FastPfu DNA Polymerase | 0.5μL |
ddH<sub>2</sub>O | 14.5μL |
pBR322/Hd | 80μL |
EcoR Ⅰ | 2μL |
BamH Ⅰ | 2μL |
Cutsmat Buffer | 10μL |
ddH<sub>2</sub>O | 6μL |
pBR322 | 5.5μL |
Hd-T7T | 2.5μL |
10×Buffer | 1μL |
T4 DNA Ligase | 1μL |
5×TransStart FastPfu Buffer | 5μL |
2.5mM dNTPs | 2μL |
模板 | 2μL |
F(上游引物) | 0.5μL |
R(下游引物) | 0.5μL |
TransStart FastPfu DNA Polymerase | 0.5μL |
ddH<sub>2</sub>O | 14.5μL |
5×TransStart FastPfu Buffer | 5μL |
2.5mM dNTPs | 2μL |
模板 | 2μL |
F(上游引物) | 0.5μL |
R(下游引物) | 0.5μL |
TransStart FastPfu DNA Polymerase | 0.5μL |
ddH<sub>2</sub>O | 14.5μL |
5×TransStart FastPfu Buffer | 10μL |
2.5mM dNTPs | 4μL |
模板 | 2μL |
F(上游引物) | 1μL |
R(下游引物) | 1μL |
TransStart FastPfu DNA Polymerase | 1μL |
ddH<sub>2</sub>O | 31μL |
pBR-Hd-NDV | 20μL |
Pme Ⅰ | 1μL |
CutSmart Buffer | 5μL |
ddH<sub>2</sub>O | 24μL |
pE-iss | 20μL |
Pme Ⅰ | 1.5μL |
CutSmart Buffer | 5μL |
ddH<sub>2</sub>O | 23.5μL |
pBR-Hd-NDV | 6μL |
pE-iss | 2μL |
10×Buffer | 1μL |
T4 DNA Ligase | 1μL |
5×TransStart FastPfu Buffer | 10μL |
2.5mM dNTPs | 4μL |
模板 | 2μL |
F(上游引物) | 1μL |
R(下游引物) | 1μL |
TransStart FastPfu DNA Polymerase | 1μL |
ddH<sub>2</sub>O | 31μL |
组别 | 攻毒毒株 | 死亡率 |
第1组 | APEC O78 | 86.67% |
第2组 | APEC O78 | 20% |
第3组 | APEC O78 | 83.33% |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010883843.6A CN112210571B (zh) | 2020-08-28 | 2020-08-28 | 表达iss基因的新城疫LaSota弱毒疫苗株反向遗传操作系统、其构建方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010883843.6A CN112210571B (zh) | 2020-08-28 | 2020-08-28 | 表达iss基因的新城疫LaSota弱毒疫苗株反向遗传操作系统、其构建方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112210571A CN112210571A (zh) | 2021-01-12 |
CN112210571B true CN112210571B (zh) | 2023-01-24 |
Family
ID=74058989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010883843.6A Active CN112210571B (zh) | 2020-08-28 | 2020-08-28 | 表达iss基因的新城疫LaSota弱毒疫苗株反向遗传操作系统、其构建方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112210571B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1772887A (zh) * | 2005-09-02 | 2006-05-17 | 中国农业科学院哈尔滨兽医研究所 | 表达禽流感病毒H5亚型HA蛋白的重组新城疫LaSota弱毒疫苗株 |
CN1772909A (zh) * | 2005-09-02 | 2006-05-17 | 中国农业科学院哈尔滨兽医研究所 | 新城疫LaSota疫苗株反向遗传操作系统及其应用 |
CN103525774A (zh) * | 2013-10-08 | 2014-01-22 | 扬州大学 | 表达传染性喉气管炎病毒gB蛋白的重组新城疫疫苗株rAI4-gB及其构建方法 |
CN104059942A (zh) * | 2013-03-20 | 2014-09-24 | 湖北省农业科学院畜牧兽医研究所 | 新城疫病毒耐热活疫苗载体系统及其应用 |
CN107557375A (zh) * | 2017-07-14 | 2018-01-09 | 河北科星药业有限公司 | tsh和iss双基因共表达菌株的构建方法及其应用 |
CN108251548A (zh) * | 2018-04-10 | 2018-07-06 | 中国农业科学院上海兽医研究所 | 禽致病性大肠杆菌等的多重pcr检测引物组、方法及试剂盒 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020102546A1 (en) * | 1998-02-12 | 2002-08-01 | Nolan Lisa K. | Nucleic acid encoding an avian E.coli iss polypeptide and methods of use |
DK2414386T3 (en) * | 2009-04-03 | 2016-02-22 | Merial Ltd | Birds of vaccines with newcastle disease virus vectors |
-
2020
- 2020-08-28 CN CN202010883843.6A patent/CN112210571B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1772887A (zh) * | 2005-09-02 | 2006-05-17 | 中国农业科学院哈尔滨兽医研究所 | 表达禽流感病毒H5亚型HA蛋白的重组新城疫LaSota弱毒疫苗株 |
CN1772909A (zh) * | 2005-09-02 | 2006-05-17 | 中国农业科学院哈尔滨兽医研究所 | 新城疫LaSota疫苗株反向遗传操作系统及其应用 |
CN104059942A (zh) * | 2013-03-20 | 2014-09-24 | 湖北省农业科学院畜牧兽医研究所 | 新城疫病毒耐热活疫苗载体系统及其应用 |
CN103525774A (zh) * | 2013-10-08 | 2014-01-22 | 扬州大学 | 表达传染性喉气管炎病毒gB蛋白的重组新城疫疫苗株rAI4-gB及其构建方法 |
CN107557375A (zh) * | 2017-07-14 | 2018-01-09 | 河北科星药业有限公司 | tsh和iss双基因共表达菌株的构建方法及其应用 |
CN108251548A (zh) * | 2018-04-10 | 2018-07-06 | 中国农业科学院上海兽医研究所 | 禽致病性大肠杆菌等的多重pcr检测引物组、方法及试剂盒 |
Non-Patent Citations (2)
Title |
---|
Milad Lagzian等.In vitro responses of chicken macrophage-like monocytes following exposure to pathogenic and non-pathogenic E. coli ghosts loaded with a rational design of conserved genetic materials of influenza and Newcastle disease viruses.《Vet Immunol Immunopathol》.2016,第176卷第5-17页. * |
赵星.致禽肾脏、肠道病变大肠杆菌菌影疫苗的制备及免疫效果的研究.《中国优秀硕士学位论文全文数据库(电子期刊)农业科技辑》.2018,D050-442. * |
Also Published As
Publication number | Publication date |
---|---|
CN112210571A (zh) | 2021-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111575247B (zh) | 一种新城疫嵌合病毒标记疫苗株及其构建方法和应用 | |
CN105420261B (zh) | 一种新城疫病毒耐热改造方法及应用 | |
CN103266091B (zh) | A型口蹄疫重组疫苗株及其制备方法和应用 | |
CN108546302B (zh) | 一种复合多表位表达盒、其组成的重组病毒及应用 | |
WO2021051906A1 (zh) | 一种针对ii类vii型流行ndv株dhn3的感染性重组克隆方法 | |
CN110218706B (zh) | 表达h7n9亚型高致病性禽流感病毒ha蛋白的重组火鸡疱疹病毒的构建与应用 | |
CN112094824B (zh) | 表达禽腺病毒4型截短Fiber2蛋白的重组新城疫病毒耐热疫苗株及其制备方法与应用 | |
CN109321534A (zh) | 一种重组基因viii型新城疫病毒弱毒株 | |
CN110079541A (zh) | 一种构建冠状病毒感染性克隆的方法及其应用 | |
CN112011521A (zh) | 一种重组新城疫病毒载体新型冠状病毒疫苗候选株及其构建方法和应用 | |
CN105087645A (zh) | M蛋白三氨基酸位点突变的猪用vsv病毒载体构建和应用 | |
US11607448B2 (en) | Whole avian-origin reverse genetic system and its use in producing H7N9 subtype avian influenza vaccine | |
US11512117B1 (en) | Whole avian-origin reverse genetic system and recombinant H5N2 subtype avian influenza virus, vaccine and uses thereof | |
WO2021051907A1 (zh) | 一种全基因组表达载体pBR322-DHN3的制备方法 | |
CN112538464A (zh) | 血清4型禽腺病毒反向遗传疫苗株rHN20及其构建方法和应用 | |
CN112210571B (zh) | 表达iss基因的新城疫LaSota弱毒疫苗株反向遗传操作系统、其构建方法及应用 | |
CN109295095A (zh) | 一种热稳定的基因viii型新城疫弱毒株外源基因表达载体 | |
CN114574452B (zh) | Hn基因易位构建重组新城疫疫苗候选株vii-hnf的方法及用途 | |
CN112891528B (zh) | 一种鸡传染性支气管炎疫苗株 | |
CN114292823A (zh) | 携带基因VII型新城疫病毒F和HN基因的重组LaSota疫苗株及其构建方法和应用 | |
CN110904056B (zh) | 一种传染性支气管炎病毒rH120-YZS1Δ5a及其构建方法和应用 | |
CN112546215A (zh) | 血清4型禽腺病毒灭活疫苗及其制备方法和应用 | |
CN117568288B (zh) | 一种高效拯救禽冠状病毒的方法及其应用 | |
CN109957550A (zh) | 流感病毒的拯救方法及其组合物 | |
CN113151193B (zh) | 血清4型禽腺病毒反向遗传疫苗株rR188I及其构建方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20210112 Assignee: Hebei jianjiale duck industry Co.,Ltd. Assignor: HEBEI KEXING PHARMACEUTICAL Co.,Ltd. Contract record no.: X2023980042130 Denomination of invention: Reverse genetic operation system, construction method, and application of LaSota attenuated Newcastle disease vaccine strain expressing iss gene Granted publication date: 20230124 License type: Common License Record date: 20230918 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20210112 Assignee: Shijiazhuang Huifeng Animal Health Products Co.,Ltd. Assignor: HEBEI KEXING PHARMACEUTICAL Co.,Ltd. Contract record no.: X2023980042236 Denomination of invention: Reverse genetic operation system, construction method, and application of LaSota attenuated Newcastle disease vaccine strain expressing iss gene Granted publication date: 20230124 License type: Common License Record date: 20230920 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20210112 Assignee: HEBEI GREENLAND ANIMAL PHARMACEUTICAL Co.,Ltd. Assignor: HEBEI KEXING PHARMACEUTICAL Co.,Ltd. Contract record no.: X2024980002521 Denomination of invention: Reverse genetic operation system for LaSota attenuated Newcastle disease vaccine strain expressing iss gene, construction method and application Granted publication date: 20230124 License type: Common License Record date: 20240305 |